@FierceBiotech: Show me the money: Which drugs made the top 10 list on upfront deals? Special Report | Follow @FierceBiotech
@JohnCFierce: Lilly draws flak after touting PhIII diabetes success for Lantus rival. More | Follow @JohnCFierce
@DamianFierce: Shire pays $260M for Lumena, getting a rare liver disease treatment and a NASH drug. Story | Follow @DamianFierce
@EmilyMFierce: Potential measles exposure in Fairfax, Loudoun counties investigated. More from The Washington Post | Follow @EmilyMFierce
> Once again, execs at Merck KGaA say that they are ready to roll out some new drug deals. Report
> Cubist released some details on the positive Phase III study it conducted for the experimental antibiotic ceftolozane/tazobactam. Story
@FierceMedDev: Report: Cinven shopping French Dx company Sebia. More | Follow @FierceMedDev
@VarunSaxena2: House votes to make R&D tax credit permanent. What will Senate do? Seems to prefer 2 year extension. Story via WSJ (sub. req.) | Follow @VarunSaxena2
@MichaelGFierce: ICYMI: Double-locked virus needs two enzyme 'keys' to release drugs. More from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Doctors weigh in on Wikipedia as an evolving--yet flawed--medical text: More from The Atlantic | Follow @EmilyWFierce
> FDA clears prescription video game for rehabilitation therapy. Article
> SI-Bone gets Medicare coverage for its spinal fusion implant. Story
> FDA approves innovative, electrode-powered robotic arm for amputees. News
Pharma News
@FiercePharma: Allergan board dismisses Valeant bid, but is it running out of options? Report | Follow @FiercePharma
@TracyStaton: Tops online this weekend: Pfizer's move on AstraZeneca outrages pols on two continents. More | Follow @TracyStaton
@EricPFierce: Problems just keep mounting up for Novartis in Japan, this time over events reporting. News | Follow @EricPFierce
@CarlyHFierce: ICYMI Friday: Pfizer prepares to file for approval with positive PhII MenB data. FierceVaccines story | Follow @CarlyHFierce
> Parsing Pfizer's deal talk isn't an exercise. It's the tell on AstraZeneca's future. Story
> Desperate to ward off Copaxone copies, Teva sues FDA. More
> On a quest to double sales, Akorn snags specialized rival VersaPharm in $440M deal. Article
CRO News
> Icon wraps up its $143.5M deal for Aptiv. Item
> China's Tigermed buys a $50M stake in a U.S. CRO. Article
> AMRI posts flat revenue as transitional year marches on. More
> Royalty Pharma backs risk-friendly researcher Avillion. Story
> Huntingdon buys Harlan Labs in a bet on CRO growth. Report
Biotech IT News
> Faced with FDA barriers, 23andMe mulls overseas expansion. Item
> U.K. tries to revive 'dead duck' patient data sharing plan. Report
> Debiopharm inks deal with Yale to access computer-aided drug discoveries. Story
> Flatiron raises $130M in Google-led round, buys EMR business. More
> DrugDev buys TrialNetworks to 'glue' its clinical trial apps together. Article